Precirix
Burgemeester Etienne Demunterlaan 3
1090 Brussel (Jette)
BE
Precirix
Foundation date
14/10/2014
Sector
#Biotechnology - TherapeuticsTherapeutic areas
Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid-derived single-domain antibodies (sdAb) labeled with radioisotopes.
The company’s lead product, CAM-H2, is being evaluated in a Phase I/II trial targeting metastatic HER2-positive cancer. Patients with tumors that overexpress HER2 can benefit from effective targeted treatments today yet have a poor prognosis when the cancer spreads. CAM-H2 aims to effectively irradiate cancer lesions while sparing healthy tissue, based on its unique technology platform that leverages the favorable tissue distribution of sdAbs.
The company’s technology platform also allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy. In addition to CAM-H2, the company has two product candidates in preclinical stage and is further broadening its platform through research on isotopes, linker technology and combination therapies.
Upcoming events
All events-
1804 '24
Anglonordic Life Science Conference 2024
Event by: BioPartner -
1605 '24
Knowledge for Growth 2024
Event by: flanders.bio -
2304 '24
BioTrinity 2024
Event by: OBN
Latest news
More news-
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
Wednesday March 27th 2024
Read more
-
InnoSer partners with CR2O to offer an integrated drug discovery to clinical trials pipeline
Tuesday March 26th 2024
Read more
-
Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy
Monday March 25th 2024
Read more
Jobs by Precirix
More jobsMore info?
Ellen Telleir
Communication Coordinator